Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
gptkb:Martha_Morrell
|
| gptkbp:FDAApproved |
2013
|
| gptkbp:focusArea |
responsive neurostimulation
|
| gptkbp:foundedYear |
1997
|
| gptkbp:founder |
gptkb:Frank_Fischer
gptkb:John_M._Williams gptkb:Martha_Morrell |
| gptkbp:headquartersLocation |
gptkb:Mountain_View,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NeuroPace
|
| gptkbp:industry |
medical devices
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableProduct |
gptkb:RNS_System
|
| gptkbp:product |
gptkb:RNS_System
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
epilepsy treatment
neuromodulation |
| gptkbp:stockSymbol |
gptkb:NPCE
|
| gptkbp:target |
drug-resistant epilepsy
|
| gptkbp:technology |
implantable device
|
| gptkbp:website |
https://www.neuropace.com/
|
| gptkbp:bfsParent |
gptkb:Mithril_Capital_Management
|
| gptkbp:bfsLayer |
5
|